Technical Analysis for KSPHF - Kissei Pharmaceutical Co. Ltd

Grade Last Price % Change Price Change
B 19.9000 2.77% 0.5370
KSPHF closed up 2.77 percent on Wednesday, January 25, 2023, on 53 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 2.77%
Gapped Down Weakness 2.77%
New 52 Week Closing High Bullish 2.26%
Narrow Range Bar Range Contraction 2.26%
New 52 Week High Strength 2.26%
Gapped Up Strength 2.26%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kissei Pharmaceutical Co. Ltd Description

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Pharmaceutical Industry Pharmaceutical Products Diabetes Organic Compounds Chemical Compounds Parkinson's Disease Dialysis Asthma Facility Management Information Processing Clinical Trial Treatment Of Parkinson's Disease Ulcerative Colitis Diabetes Mellitus Overactive Bladder Benign Prostatic Hyperplasia Silodosin Epoetin Alfa Hyperphosphatemia Uterine Fibroids

Is KSPHF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 19.9
52 Week Low 17.71
Average Volume 1,333
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
RSI 0.00
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.9000
Resistance 3 (R3) 19.9000 19.9000 19.9000
Resistance 2 (R2) 19.9000 19.9000 19.9000 19.9000
Resistance 1 (R1) 19.9000 19.9000 19.9000 19.9000 19.9000
Pivot Point 19.9000 19.9000 19.9000 19.9000 19.9000
Support 1 (S1) 19.9000 19.9000 19.9000 19.9000 19.9000
Support 2 (S2) 19.9000 19.9000 19.9000 19.9000
Support 3 (S3) 19.9000 19.9000 19.9000
Support 4 (S4) 19.9000